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Abstract
Dexamethasone administration prior to tonsillectomy has been shown to reduce morbidity and is part of SIGN guideline 117. We conducted a
three-cycle audit of 149 patients to ascertain how well guidelines were being met and introduce a sustainable method to improve compliance.
A 3-month audit was conducted to ascertain how many tonsillectomy patients didn’t receive pre-operative dexamethasone. ENT secretaries
were requested to add ‘Dex Please’ to tonsillectomy theatre lists. A 3-month re-audit was conducted; the intervention was only implemented in
half of cases and so a reminding tool for the secretarial staff was administered before a third cycle. Initially, there was 73% compliance to
SIGN guidelines, this improved to 87% in the second cycle. After the second intervention, all tonsillectomy theatre lists had the ‘Dex Please’
note and compliance to SIGN guidelines was 100%. There were five readmissions in the first cycle, three in the second and two in the third
cycle. All readmissions were underdosed according to guidelines. Understanding there are regular staff rotations throughout many U.K.
hospitals, we implemented a reliable method to increase compliance to guidelines which helped reduce post-operative readmission after
tonsillectomy. This can be easily introduced to other institutions and for other perioperative requirements.
Problem
Dexamethasone provides a low cost and relatively safe method to
reduce post-operative complications in tonsillectomy patients [1].
Despite this evidence, failure to administer dexamethasone still
results in unplanned admissions [2], causing unnecessary costs to
the National Heath Service. We conducted a three-cycle audit of
perioperative dexamethasone use in patients undergoing
tonsillectomy at our hospital, a Trust that performs approximately
300 elective tonsillectomies per year, the majority being paediatric
cases. This was done directly after identifying two unplanned
admissions in tonsillectomy patients that did not receive
perioperative dexamethasone.
Background
Dexamethasone is a systemic corticosteroid that is commonly
administered as prophylaxis for post-operative nausea and vomiting
(PONV) during surgical procedures due to its anti-inflammatory
properties. Perioperative dexamethasone has been shown to
reduce post-operative morbidity in tonsillectomy patients by
shortening the time to return to a normal diet [3] and after more than
thirty years of data supporting its use [4], the administration of
dexamethasone during anaesthetic induction prior to starting a
tonsillectomy has become the standard of care in many institutions.
SIGN Guideline 117 state that:
1. A single intraoperative dose of dexamethasone (dose range
0.15 to 1.0 mg/kg; maximum dose range 8 to 25mg) is
recommended to prevent postoperative vomiting in children
undergoing tonsillectomy or adenotonsillectomy.
2. A single dose of 10 mg dexamethasone at induction of
anaesthesia may be considered to prevent PONV in adults
undergoing tonsillectomy or adenotonsillectomy.
Baseline measurement
To quantify the problem, a retrospective audit of compliance with
SIGN Guideline 117 was conducted between 1st July and 1st
September 2013. A review of 48 anaesthetic charts revealed that
perioperative dexamethasone was not given in 27% of patients
(n=13). Of these, 75% (n=36) were paediatric patients (defined as
patients under the age of 18 years that had undergone a paediatric
perioperative assessment). Results were presented to the
anaesthetic and ENT departments who agreed that a sustainable
intervention should be implemented.
See supplementary file: ds4996.docx - “Tables 1-3”
Design
With regular staff rotation and temporary doctors throughout most
UK hospitals, we acknowledged that a sustainable intervention had
to be implemented to ensure lasting improvement in perioperative
dexamethasone administration.
For the second cycle, data was collected prospectively between 1st
February 2014 and 1st April 2014. Anaesthetic charts were used to
ascertain whether dexamethasone was given perioperatively in
adult and paediatric patients undergoing tonsillectomy.
Tonsillectomy for recurrent tonsillitis, sleep apnoea, and diagnostic
biopsy were included. Postoperative complications were also
recorded. Bleeding events that occurred within the first 24 hours
were considered as primary bleeds, episodes after this were
considered secondary bleeding episodes.
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After further intervention, a third audit cycle was prospectively
conducted between 1st July 2014 and 1st September 2014.
Strategy
Study aims:
1.  Measure compliance with SIGN Guideline 177, specifically
perioperative administration of dexamethasone.
2.  Create a sustainable intervention to improve compliance
with this guideline.
3.  Ascertain whether this translates to an improvement in
clinical outcome.
PDSA Cycle 1
We aimed to place the reminder for dexamethasone on all
tonsillectomy listings. A request was made to the ENT secretaries
to add a reminder to the online and printed theatre list by inserting
"Dex Pls" in the general comments section (Table 1). On review of
the theatre lists, we found that our intervention had not been
implemented in 50% of tonsillectomy cases. Where it was
implemented, administration of dexamethsone was discussed in the
Team Brief at the start of the operating list. It was only by prompting
this discussion that the ENT surgeons first realised the concerns of
some anaesthetist for the potential side effects of steroids.
PDSA Cycle 2
Understanding that new practices such as additions to theatre lists
are difficult to establish, a reminding poster was created for the ENT
secretaries' office. This resulted in the intervention being
implemented on 100% of theatre lists for the third cycle. The
reminder prompted discussion between all members of the theatre
team in case any staff member felt that perioperative
dexamethasone was inappropriate for a particular case. The ENT
surgeons no longer took for granted that SIGN Guideline 117 was
known to other staff members.
Results
Dexamethasone administration
In the second cycle, 59 anaesthetic charts were audited, of which
54 were adequately completed for analysis. Paediatric patients
account for 59% of audited charts (n=32). We found that
perioperative dexamethasone use had increased to 87%. In the
third cycle, 52 anaesthetic charts were audited of which 48 were
adequately complete for analysis. One patient was excluded as
they were on long term steroid treatment therefore a reason for
dexamethasone omission had been documented. The intervention
was now implemented for all tonsillectomy cases and
dexamethasone was given perioperatively in 100% of patients
(Table 2).
Dexamethasone dosing
In the second cycle, we found legible doses for 24 paediatric
patients of which the average dexamethasone dose was
0.08mg/kg. Only one paediatric patient received the recommended
0.15mg/kg-1.0mg/kg (Figure 1). All other paediatric patients were
under-dosed according to the guideline. For adult tonsillectomies,
no patient received the recommended single dose of 10mg, the
average being 4.6mg (range 3.3-8mg).
There was a small improvement in dexamethasone dosing for the
third cycle, with the average paediatric dosing being 0.10mg/kg.
Again no adult patient received the recommended 10mg single
dose but the average dose was higher at 5.2mg (range 3.3-8mg).
Post-operative complications
There were 6 post-tonsillectomy readmissions in the first cycle,
three in the second, and two in the third. Most of the re-admissions
were given lower doses of dexamethasone (Figure 1). The reasons
for readmission were post-operative pain, vomiting, and secondary
bleeding episode (Table 3). The mainstay of treatment for the
unplanned admission was opioid analgesia and intravenous
antibiotics. There were no primary bleeds in the audited study
periods and all tonsillectomies were conducted with variations of
cold steel, ties, and bipolar haemostasis.
See supplementary file: ds4997.png - “Figure 1. Perioperative
dexamethasone doses in paediatric patients (readmissions
circled).”
Lessons and limitations
SIGN Guideline 117 is based on several meta-analyses and
Cochrane reviews, however the assumption that these guidelines
are known and accepted by the Anaesthetic department was
incorrect as highlighted by this audit. A UK survey of anaesthetists
reported that only 61% routinely used dexamethasone during
tonsillectomy procedures [5], highlighting that this problem is not
limited to our Trust. Whilst the risks of steroid therapy include
immune system suppression and avascular joint necrosis, a single
dose has been shown to be virtually without harmful effects [6],
although the potential risks and benefits can be discussed with the
patient or the parents.The audit interventions prompted case based
discussion and learning within the team.
Despite the promising results, most patients who received pre-
operative dexamethasone were under-dosed which may still
influence post-operative morbidity. There is evidence to support
giving the lower end of the recommended dexamethasone range
[7], however the results of this audit show that guidelines are not
being met in reference to dosing. A follow on from this study would
be an intervention to address anaesthetic pre-conceptions on
dosing of perioperative steroids. This would ideally be a multi-
departmental quality improvement project.
Conclusion
This three cycle audit against SIGN Guideline 117 demonstrated a
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sustained improvement in practice, with two successful
interventions resulting in 100% of tonsillectomy patients receiving
perioperative dexamethasone. This also led to a reduction in the
post-operative readmission rate, with no patients being readmitted
with pain and/or nausea. Appreciating that trainees rotate regularly
between hospital trusts, it was important to recruit assistance from
the staff members that do not rotate between hospitals to help
introduce a sustainable intervention.
We recommend the use of the ‘general comments’ section on
theatre lists as a maintainable way to improve patient care and
reduce unnecessary costs to the hospital. Although not specifically
targeted by our audit, we discovered a widespread practice of
dexamethaone underdosing, which was only mildly improved and
still needs to be addressed.
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